These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37115807)

  • 1. Association Between Bruton's Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren's Syndrome.
    Duret PM; Schleiss C; Kawka L; Meyer N; Ye T; Saraux A; Devauchelle-Pensec V; Seror R; Larroche C; Perdriger A; Sibilia J; Vallat L; Fornecker LM; Nocturne G; Mariette X; Gottenberg JE
    Arthritis Rheumatol; 2023 Oct; 75(10):1798-1811. PubMed ID: 37115807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome.
    Kapsogeorgou EK; Papageorgiou A; Protogerou AD; Voulgarelis M; Tzioufas AG
    Ann Rheum Dis; 2018 Aug; 77(8):1200-1207. PubMed ID: 29779010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome.
    Tobón GJ; Saraux A; Gottenberg JE; Quartuccio L; Fabris M; Seror R; Devauchelle-Pensec V; Morel J; Rist S; Mariette X; De Vita S; Youinou P; Pers JO
    Arthritis Rheum; 2013 Dec; 65(12):3218-27. PubMed ID: 23982978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome.
    Anaya JM; McGuff HS; Banks PM; Talal N
    Semin Arthritis Rheum; 1996 Apr; 25(5):337-46. PubMed ID: 8778989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.
    Nocturne G; Seror R; Fogel O; Belkhir R; Boudaoud S; Saraux A; Larroche C; Le Guern V; Gottenberg JE; Mariette X
    Arthritis Rheumatol; 2015 Dec; 67(12):3226-33. PubMed ID: 26359802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The P2X7 receptor-NLRP3 inflammasome complex predicts the development of non-Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single-centre study.
    Baldini C; Santini E; Rossi C; Donati V; Solini A
    J Intern Med; 2017 Aug; 282(2):175-186. PubMed ID: 28503820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sjögren's syndrome associated with non-Hodgkin's lymphoma].
    Nagai K
    Nihon Rinsho; 1995 Oct; 53(10):2574-9. PubMed ID: 8531376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease.
    Corneth OBJ; Verstappen GMP; Paulissen SMJ; de Bruijn MJW; Rip J; Lukkes M; van Hamburg JP; Lubberts E; Bootsma H; Kroese FGM; Hendriks RW
    Arthritis Rheumatol; 2017 Jun; 69(6):1313-1324. PubMed ID: 28141917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.
    Nocturne G; Virone A; Ng WF; Le Guern V; Hachulla E; Cornec D; Daien C; Vittecoq O; Bienvenu B; Marcelli C; Wendling D; Amoura Z; Dhote R; Lavigne C; Fior R; Gottenberg JE; Seror R; Mariette X
    Arthritis Rheumatol; 2016 Apr; 68(4):977-85. PubMed ID: 26606524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased BAFF Receptor Expression and Unaltered B Cell Receptor Signaling in Circulating B Cells from Primary Sjögren's Syndrome Patients at Diagnosis.
    Neys SFH; Verstappen GM; Bootsma H; Kroese FGM; Hendriks RW; Corneth OBJ
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome.
    Valesini G; Priori R; Bavoillot D; Osborn J; Danieli MG; Del Papa N; Gerli R; Pietrogrande M; Sabbadini MG; Silvestris F; Valsecchi L
    J Rheumatol; 1997 Dec; 24(12):2376-80. PubMed ID: 9415645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sjögren's syndrome.
    Cinoku II; Verrou KM; Piperi E; Voulgarelis M; Moutsopoulos HM; Mavragani CP
    J Autoimmun; 2021 Sep; 123():102704. PubMed ID: 34298409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study.
    Chiu YH; Chung CH; Lin KT; Lin CS; Chen JH; Chen HC; Huang RY; Wu CT; Liu FC; Chien WC
    Oncotarget; 2017 Jul; 8(30):50098-50108. PubMed ID: 28177920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome.
    Chatzis L; Goules AV; Stergiou IE; Voulgarelis M; Tzioufas AG; Kapsogeorgou EK
    Front Immunol; 2021; 12():705079. PubMed ID: 34484201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
    Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
    PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?
    Nezos A; Skarlis C; Psarrou A; Markakis K; Garantziotis P; Papanikolaou A; Gravani F; Voulgarelis M; Tzioufas AG; Koutsilieris M; Moutsopoulos HM; Kotsifaki E; Mavragani CP
    Front Immunol; 2021; 12():683623. PubMed ID: 34220834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment.
    Routsias JG; Goules JD; Charalampakis G; Tzima S; Papageorgiou A; Voulgarelis M
    Semin Arthritis Rheum; 2013 Oct; 43(2):178-86. PubMed ID: 23816048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma.
    Carbone J; Perez-Fernandez R; Muñoz A; Sabin P; Carreño L; Fernandez-Cruz E
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):80-4. PubMed ID: 18270861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren's Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study.
    Ben-Eli H; Aframian DJ; Ben-Chetrit E; Mevorach D; Kleinstern G; Paltiel O; Solomon A
    J Immunol Res; 2019; 2019():9060842. PubMed ID: 30805374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoma development in Sjögren's syndrome: novel p53 mutations.
    Tapinos NI; Polihronis M; Moutsopoulos HM
    Arthritis Rheum; 1999 Jul; 42(7):1466-72. PubMed ID: 10403275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.